This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:publications:mp2008_survey [04.24.2009] – neldawhite | home:publications:mp2008_survey [05.02.2011] – external edit 127.0.0.1 | ||
---|---|---|---|
Line 1: | Line 1: | ||
+ | | ||
+ | At the 6th International Congress on Autoimmunity in Porto, Portugal, Capt. Tom Perez MPH gave a presentation entitled [[perez_congress_on_autoimmunity_2008|Bacteria induced Vitamin D Receptor Dysfunction in Autoimmune Disease: Theoretical and practical Implications for Interpretation of Serum Vitamin D Metabolite Levels]]. The data in the presentation was based on a survey conducted over the course of 2007 and 2008 of 100 Marshall Protocol (MP) patients with autoimmune diagnoses. | ||
+ | |||
+ | Patients were asked if the severity of their symptoms had changed while on the MP and, if so, how much. Improvement was reported by symptom. | ||
+ | |||
+ | The results of the survey indicate that the Marshall Protocol resolves symptoms of autoimmune disease over the course of multiple years. | ||
+ | ===== Methods ===== | ||
+ | |||
+ | |||
+ | Joyce Waterhouse, PhD created an 18-question survey in 2007. Surveys were distributed via email to 150 patients in the late part of 2007 and early part of 2008. Of the 115 surveys returned, 100 met the criteria for inclusion in the survey. Certain patients were excluded: | ||
+ | * unconfirmed diagnosis (n = 9) | ||
+ | * less than one month on Protocol (n = 1) | ||
+ | * insufficient data/ | ||
+ | * severe noncompliance (n = 4) | ||
+ | |||
+ | Multiple efforts were made to follow up with people who had not completed the survey. | ||
+ | |||
+ | As this data was to be presented at the 2008 Congress on Autoimmunity, | ||
+ | |||
+ | Responses from patients who discontinued the MP prior to the survey were also included (n = 3). | ||
+ | |||
+ | The small size of the survey does not lend itself to providing enough data about any particular condition to make strong assertions, but does offer provocative data that invites further research. | ||
+ | |||
+ | |||
+ | |||
+ | < | ||
+ | |||
+ | The response rate (percent who completed the survey of those who were sent it) among those with only fibromyalgia (from the list of conditions we surveyed) was lower -- 50%. I speculate that the lower response rate may be that they think they have more options, as there are so many alternative medicine approaches that are marketed to them and so perhaps they feel less willing to stick out the IP. I don't think we can conclude it is necessarily that they have more trouble or something -- we just don't know. | ||
+ | |||
+ | // | ||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | ===== Results ===== | ||
+ | |||
+ | |||
+ | |||
+ | ==== General response to treatment ==== | ||
+ | |||
+ | MP patients reported a year-by-year increase in average net improvement in symptom severity. The number of patients reporting improvement who have been on the treatment for any given length of time also had an upward trend. | ||
+ | |||
+ | |||
+ | {{home: | ||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | ==== Symptom improvement | ||
+ | |||
+ | The following chart illustrates the proportion of patients with a given disease who reported they have improved. | ||
+ | |||
+ | |||
+ | {{: | ||
+ | |||
+ | |||
+ | Note that one cannot simply add up the numbers on the chart. Some patients had multiple diagnoses and would be counted for each. If they had thyroiditis and fibromyalgia for instance, and both conditions had improved, they would show as improved cases in both parts of the chart. If one improved and the other did not, they would show up as improved for one and not for the other. | ||
+ | |||
+ | Also note that the numbers for "not improved" | ||
+ | |||
+ | |||
+ | ==== Symptom level change on olmesartan alone ==== | ||
+ | |||
+ | 64 patients provided a response to this question on the survey. The question asked about changes in symptom level when on Benicar only (at the start of the Marshall Protocol). | ||
+ | |||
+ | * 30% reported their symptom level was the same when on Benicar alone | ||
+ | * 39% reported their symptom level was better when on Benicar alone | ||
+ | * 31% reported their symptom level was worse when on Benicar alone | ||
+ | |||
+ | |||
+ | ==== Changes in inhalant allergies ==== | ||
+ | |||
+ | 22 patients who had inhalant allergies prior to starting the Marshall Protocol (and having been on the protocol 18 months or longer) provided these answers about changes in response to inhalant allergens. | ||
+ | |||
+ | * 77% reported their inhalant allergies were better (17/22) | ||
+ | * 14% reported their inhalant allergies were the same (3/22) | ||
+ | * 9% reported their inhalant allergies were worse (2/22) | ||
+ | ===== Notes on interpretation ===== | ||
+ | |||
+ | * The responses to the survey were a " | ||
+ | * The limited size of the sample, 100 patients, introduces a certain amount of random variability. One could perform a statistical test on the slight drop between patients in year 3 or year 4 and find that there' | ||
+ | * The patients on the MP are self-selected. Arguably, many of them were so sick that they were driven to start the MP as a measure of desperation. It would be reasonable to expect that a person with less severe disease symptoms would take less time on the MP. | ||
+ | |||
+ | < | ||
+ | |||
+ | // | ||
+ | {{tag> }} | ||
+ | |||
+ | ===== Notes and comments ===== | ||
+ | |||
+ | * We should include some of the survey questions, so readers know what was asked. ... Ok, I'll work on that. -//J// | ||
+ | * < | ||
+ | * I love this chart. | ||
+ | * It doesn' |